The Michael J. Fox Foundation for Parkinson’s Research & The New York Academy of Sciences
Parkinson’s Disease Therapeutics Conference
New York, NY
October 24, 2012

Poster Session on Novel Therapeutic Targets and Tools

Lily Cappelletti, The Michael J. Fox Foundation for Parkinson’s Research – “Innovative Web-based Matching Service, Fox Trial Finder, as a Mechanism to Improve Parkinson’s Clinical Trial Recruitment”

Kuldip Dave, PhD, The Michael J. Fox Foundation for Parkinson’s Research – “MJFF Animal Models: Phenotypic characterization of the autosomal recessive (Parkin, Pink-1 and DJ-1) gene knockout rat models of Parkinson’s disease”

Jamie Eberling, PhD, The Michael J. Fox Foundation for Parkinson’s Research – “The Parkinson Progression Marker Initiative (PPMI) - Baseline Data”

Martin Martinov, PhD, Gradient Biomodeling – “Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PD”

Manisha Patel, PhD, University of Colorado Denver - “Optimizing Metalloporphryins for Clinical Development”

Joel S. Perlmutter, MD, Washington University in St. Louis - “Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons”

Beverly Rzigalinski, PhD, Virginia College of Osteopathic Medicine – “Cerium Oxide Nanoparticles in Treatment of Parkinson’s Disease”

Yvonne Schmitz, PhD, Columbia University - “Glyt1 Inhibitors Promote Dopaminergic Striatal Sprouting”

Kathleen M. Shannon, MD, Rush Medical College - “Intestinal Permeability, Exposure to Lipopolysaccharide, and Alpha-Synuclein Aggregation in Parkinson's Disease”

David K. Simon, MD, PhD, Beth Israel Deaconess Medical Center and Harvard Medical School – “PGC-1 Alpha as a Neuroprotective Target in Parkinson's Disease”

David M. White, PhD, University of Chicago - “Oxidized DJ-1 as a Biomarker for Parkinson's Disease”